|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: B3GALNT1 |
Gene summary for B3GALNT1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | B3GALNT1 | Gene ID | 8706 |
| Gene name | beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group) | |
| Gene Alias | B3GALT3 | |
| Cytomap | 3q26.1 | |
| Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | O75752 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8706 | B3GALNT1 | LZE24T | Human | Esophagus | ESCC | 1.10e-07 | 1.33e-01 | 0.0596 |
| 8706 | B3GALNT1 | P2T-E | Human | Esophagus | ESCC | 1.13e-36 | 7.73e-01 | 0.1177 |
| 8706 | B3GALNT1 | P4T-E | Human | Esophagus | ESCC | 4.48e-12 | 2.69e-01 | 0.1323 |
| 8706 | B3GALNT1 | P5T-E | Human | Esophagus | ESCC | 9.76e-05 | 1.54e-01 | 0.1327 |
| 8706 | B3GALNT1 | P8T-E | Human | Esophagus | ESCC | 8.22e-19 | 3.51e-01 | 0.0889 |
| 8706 | B3GALNT1 | P9T-E | Human | Esophagus | ESCC | 1.67e-08 | 9.69e-02 | 0.1131 |
| 8706 | B3GALNT1 | P10T-E | Human | Esophagus | ESCC | 2.74e-27 | 3.16e-01 | 0.116 |
| 8706 | B3GALNT1 | P11T-E | Human | Esophagus | ESCC | 4.29e-03 | 1.49e-01 | 0.1426 |
| 8706 | B3GALNT1 | P16T-E | Human | Esophagus | ESCC | 7.50e-27 | 5.24e-01 | 0.1153 |
| 8706 | B3GALNT1 | P20T-E | Human | Esophagus | ESCC | 3.61e-17 | 3.53e-01 | 0.1124 |
| 8706 | B3GALNT1 | P21T-E | Human | Esophagus | ESCC | 1.06e-17 | 2.76e-01 | 0.1617 |
| 8706 | B3GALNT1 | P23T-E | Human | Esophagus | ESCC | 1.07e-14 | 2.71e-01 | 0.108 |
| 8706 | B3GALNT1 | P24T-E | Human | Esophagus | ESCC | 4.42e-05 | 1.61e-02 | 0.1287 |
| 8706 | B3GALNT1 | P26T-E | Human | Esophagus | ESCC | 1.53e-10 | 1.39e-01 | 0.1276 |
| 8706 | B3GALNT1 | P27T-E | Human | Esophagus | ESCC | 1.47e-09 | 1.42e-01 | 0.1055 |
| 8706 | B3GALNT1 | P28T-E | Human | Esophagus | ESCC | 8.37e-06 | 4.53e-02 | 0.1149 |
| 8706 | B3GALNT1 | P31T-E | Human | Esophagus | ESCC | 3.26e-04 | 2.77e-02 | 0.1251 |
| 8706 | B3GALNT1 | P32T-E | Human | Esophagus | ESCC | 5.20e-12 | 5.63e-02 | 0.1666 |
| 8706 | B3GALNT1 | P36T-E | Human | Esophagus | ESCC | 7.26e-05 | 2.52e-01 | 0.1187 |
| 8706 | B3GALNT1 | P39T-E | Human | Esophagus | ESCC | 3.16e-02 | 4.98e-02 | 0.0894 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00066433 | Esophagus | ESCC | membrane lipid metabolic process | 130/8552 | 203/18723 | 9.29e-08 | 1.54e-06 | 130 |
| GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
| GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
| GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00434135 | Esophagus | ESCC | macromolecule glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
| GO:00066652 | Esophagus | ESCC | sphingolipid metabolic process | 96/8552 | 155/18723 | 3.21e-05 | 2.66e-04 | 96 |
| GO:00160514 | Esophagus | ESCC | carbohydrate biosynthetic process | 117/8552 | 202/18723 | 2.96e-04 | 1.79e-03 | 117 |
| GO:00066642 | Esophagus | ESCC | glycolipid metabolic process | 63/8552 | 100/18723 | 3.55e-04 | 2.06e-03 | 63 |
| GO:19035092 | Esophagus | ESCC | liposaccharide metabolic process | 63/8552 | 101/18723 | 5.25e-04 | 2.90e-03 | 63 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| B3GALNT1 | SNV | Missense_Mutation | c.247C>G | p.Leu83Val | p.L83V | O75752 | protein_coding | deleterious(0) | possibly_damaging(0.852) | TCGA-AR-A2LH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| B3GALNT1 | SNV | Missense_Mutation | novel | c.373N>C | p.Glu125Gln | p.E125Q | O75752 | protein_coding | tolerated(0.18) | benign(0.007) | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
| B3GALNT1 | SNV | Missense_Mutation | novel | c.736T>C | p.Ser246Pro | p.S246P | O75752 | protein_coding | deleterious(0.02) | probably_damaging(0.972) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| B3GALNT1 | SNV | Missense_Mutation | c.935N>T | p.Ser312Phe | p.S312F | O75752 | protein_coding | deleterious(0.01) | possibly_damaging(0.496) | TCGA-BI-A0VS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| B3GALNT1 | SNV | Missense_Mutation | c.552N>A | p.Phe184Leu | p.F184L | O75752 | protein_coding | deleterious(0.02) | benign(0.157) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| B3GALNT1 | SNV | Missense_Mutation | c.395N>T | p.Ser132Phe | p.S132F | O75752 | protein_coding | deleterious(0.01) | probably_damaging(0.951) | TCGA-VS-A8EB-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | PD | |
| B3GALNT1 | SNV | Missense_Mutation | rs780802727 | c.139N>A | p.Val47Met | p.V47M | O75752 | protein_coding | tolerated(0.26) | benign(0.05) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| B3GALNT1 | SNV | Missense_Mutation | c.778N>A | p.Val260Ile | p.V260I | O75752 | protein_coding | tolerated(0.94) | benign(0.058) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| B3GALNT1 | SNV | Missense_Mutation | rs752083614 | c.434N>A | p.Arg145Gln | p.R145Q | O75752 | protein_coding | tolerated(0.69) | benign(0.007) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| B3GALNT1 | SNV | Missense_Mutation | rs752083614 | c.434N>A | p.Arg145Gln | p.R145Q | O75752 | protein_coding | tolerated(0.69) | benign(0.007) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |